BECOME MEMBER SUPPORT
Year Cancer type Speaker
Lung Cancer Update - 18 February 2022
Welcome & Introduction
Role of Alecensa in 1L ALK+ NSCLC patients Beyond The Barriers
Lorlatinib as a first line option for ALK positive metastatic NSCLC
Video and slides 
CRSF Asco list of publications 
Ongoing studies 